1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Merdury Biopharmaceutical Corporation

Merdury Biopharmaceutical Corporation

TTPEX:6932
5.91
TWD
-0.11
(-1.83%)
2.58BMarket Cap
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
0.01
- -
0.01
- -
- -
Basic EPS, GAAP
- -
- -
-0.02
-0.08
-0.11
-0.12
-0.16
- -
Free Cash Flow per Basic Share
- -
- -
-0.04
-0.25
-0.14
-0.11
-0.14
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
0.03
0.44
0.93
0.7
0.53
0.47
Tangible Book Value per Share
- -
- -
0.02
0.44
0.93
0.69
0.51
0.46
Basic Weighted Avg Shares
351
105
278
379
410
416
419
422
Sales/Revenue/Turnover
- -
- -
- -
3
1
5
- -
- -
Operating Margin (%)
- -
- -
- -
-1,152.91
-4,423.04
-1,088.9
- -
- -
Depreciation Expense
- -
- -
1
3
4
7
12
- -
Net Income, GAAP
- -
- -
-5
-31
-44
-51
-67
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
-1,166.04
-4,241.63
-1,018.9
- -
- -
Working Capital
- -
- -
2
138
332
224
155
132
LT Debt
- -
- -
1
42
42
44
39
40
Total Equity
- -
- -
10
180
388
290
220
201
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
-32.76
-15.41
-14.9
-26.37
- -

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
5
3
3
LT Borrowings
39
38
37
LT Finance Leases
3
1
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
415
417
428
Market Capitalization
4,377
3,462
2,583

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
209
175
152
Cash, Cash Equivalents & STI
199
164
136
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
2
Total Current Liabilities
23
20
20
Payables & Accruals
- -
- -
- -
ST Debt
5
3
3
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-682.48%
-24.32%
Free Cash Flow
- -
1,240.43%
26.91%
Net Income, GAAP
- -
601.06%
32.95%
Sales/Revenue/Turnover
- -
- -
-100%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
5
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.12
2025
- -
- -
-0.16
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Yao Jen Liang
Full Time Employees
19
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 653, Bannan Rd. New Taipei City TP Taiwan 235030
IPO Date
Dec 23, 2022
Website
merdury.com.tw
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Mercury Biopharmaceutical Corporation (6932.TWO), also known as Merdury Biopharmaceutical Corporation, engages in the development of specialty pharmaceuticals addressing unmet medical needs through innovative drug delivery technologies in Taiwan. The company develops the proprietary StackDose platform, which enables precise time-controlled dissolution, site-specific absorption, and adjustable dosages to improve bioavailability, reduce active pharmaceutical ingredient quantities, and minimize side effects; it focuses on rapid-acting and specialty drugs targeting erectile dysfunction, pulmonary hypertension, sleep disorders, benign prostatic hyperplasia, angina pectoris, migraine, anti-hypertension, and analgesics. Founded in 2019 and headquartered at 15F, No. 653-1, Bannan Road, Zhonghe District, New Taipei City, Taiwan, the company operates primarily in the pharmaceuticals and biotechnology sector, with its shares listed on the Taipei Exchange since December 2022. Merdury positions itself as a global leader in 3D powder printing pharmaceutical technology, evolving its branding from Mercury to Merdury to emphasize advancements in this area and support its mission of delivering innovative medicines inspired by the messenger god Hermes. The company maintains a focus on difficult generic drugs and second-class new drugs without reported major acquisitions, partnerships, funding rounds, or product launches in the past 1-2 years, concentrating instead on platform maturation and pipeline progression under CEO Yaoren Liang.